Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant)

Marta Anna Sobas, Natalia Alonso Vence, Jose Diaz Arias, Angeles Bendaña Lopez, Maximo Fraga Rodriguez, Jose Luis Bello Lopez

To cite this version:

HAL Id: hal-00535081
https://hal.archives-ouvertes.fr/hal-00535081
Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Dear Editor,

Castleman’s disease is a rare lymphoproliferative disorder with a variable clinical course [1]. Multicentric Castleman disease (MCD) presents with generalized lymphadenopathy, hepatosplenomegaly, fever, and night sweats, and aggressive treatment is required [2]. Viral infections, autoimmunity disorders, and altered cytokine (IL-6) regulation have been implicated in CD pathogenesis [2, 3]. The association between CD and POEMS syndrome is well known [4].

A 49-year-old male, diagnosed of depressive disorder, and dysmyelinating peripheral polyneuropathy presented in June 2001 with asthenia, anorexia, generalized edema, and diarrhea. Physical examination revealed rash, left axial adenopathy, and distal dysesthesia in superior extremities. Normochromic anemia with slight leukocytosis was observed. Total protein and immunoglobulin levels were normal. No monoclonal protein was detected. Beta-2 microglobulin was increased to 3.19 mg/L (normal=0.3–2.1 mg/L). LDH levels and hepatic and kidney functions were normal. Osteosclerotic lesions in ribs were detected on radiographs. Bone marrow biopsy was infiltrated by polyclonal linfo-plasmocytic population. A computed tomography (CT) scan showed multiple intra-abdominal adenopathies, splenomegaly with ascites, and pleural effusion. An axial node biopsy was nondiagnostic, and abdominal lymph node biopsy was compatible with CD (Fig. 1). On the days following biopsy, a rapid progression of ascites and pleural effusion with subsequent hemodynamic instability was observed. A thoracocentesis showed exudative pleural fluid with increased IL-6 levels reaching 1,640 pg/mL. Serum IL-6 levels were increased to 69.8 pg/mL (normal <5 pg/mL). Clinical improvement was achieved by intravenous steroid therapy. Screening for human immunodeficiency virus (HIV) and human herpes virus-8 (HHV-8) was negative. Throughout the following 2 years, the patient was asymptomatic with low dose of steroids. In 2003, progression of ascites and pleural effusion was observed, and anti-CD20 antibodies (Rituximab 375 mg/m², four doses weekly) was applied without any response. In 2004, four courses of CHOP (excluding vincristine, so as not to worsen the patient’s polyneuropathy) were administered with a partial response. In subsequent years, the patient experienced progressive deterioration with asthenia, anorexia, weight loss, and an increase in ascites and pleural effusion. The condition was moderately sensitive to repeated steroid treatment; however, in 2005, he was admitted because of an esophagus variceal hemorrhage, and Budd–Chiari syndrome was diagnosed by CT study. In 2006, primary hypothyroidism was detected, and supplementary therapy was started. In 2006, due to the lack of treatment response and no other available therapeutic options, informed consent was obtained to initiate therapy with bortezomib at a dosage of 1.3 mg/m² combined with 20 mg of dexamethasone on days 1, 4, 8, 11, repeated at day 22 for a total of six cycles. A strict control of neurological toxicity of bortezomib was per-
formed, as the patient presented peripheral polyneuropathy. The treatment was well tolerated, and after the third cycle, improvement was observed (Table 1). Four years later, the patient remains in complete remission.

The diagnosis of MCD is based on lymph node histopathology study, presence of multiple adenopathies, and constitutional symptoms [2]. However, in our patient, the presence of peripheral neuropathy, primary hypothyroidism, effusions, and skin changes forced us to change the diagnosis to MCD-POEMS variant [4]. According to the literature, polyclonal hypergammaglobulinemia is often present [4]. In the present case, polyclonal hypergammaglobulinemia was found and no monoclonal protein was detected in spite of repeatedly performing immunofixation electrophoresis studies of serum and urine. We could not determine the clonality state of plasma cells from osteosclerotic lesions because biopsy consent was not obtained. As in the literature, polyclonal plasmatic cells were found in bone marrow study, and cytokine IL-6 levels were high [4].

There is still no consensus regarding the “gold standard” therapy in CD [2]. Chemotherapy (CHOP or CVAD) has shown response rates around 90%, with 50% showing complete response [5]. In our patient’s case, only a partial response was achieved. Steroids can control inflammation [2] and improve response rates. Although these effects may be transient, they appear in about 60% of patients [5]. Interferon-alpha (INF-alpha) has both immunoregulatory and antiviral properties, making it a potentially effective therapy for patients with MCD [2]. Thalidomide, similar to INF-alpha, also has immunomodulatory, anti-angiogenic properties. In addition, thalidomide can decrease the production of IL-6 [2]. Our patient suffered from depressive disorder and polyneuropathy, thus, the reason why INF-alpha and thalidomide were not used. Although therapeutic efficacy of antibody anti-IL6 receptor and anti-IL6 were reported [6, 7], we did not have access to these drugs. Positive outcomes have been published regarding treatment with the anti-CD20 drug Rituximab [5]; in case of our patient, no response was obtained. Other therapeutic approaches such as the antiviral agents yielded nondurable response or no improvement [8, 9]. As our patient was HIV and HHV-8 negative, antiviral agents were not used. Finally, good response to melphalan-based autologous transplant was observed in patients with neuropathy related to POEMS with or without CD [10]. Nevertheless, in this

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Therapy with bortezomib and patient outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-bortezomib</td>
</tr>
<tr>
<td>ECOG</td>
<td>4</td>
</tr>
<tr>
<td>Adenopathies</td>
<td>Axial, multiple mediastinoc and intra-abdominal</td>
</tr>
<tr>
<td>Pleural effusion and ascites</td>
<td>Progressive, no response to the treatment</td>
</tr>
<tr>
<td>Heptoesplenomegaly</td>
<td>Progressive, no response to the treatment</td>
</tr>
<tr>
<td>Dysmyelinating peripheral polyneuropathy</td>
<td>Distal dysesthesia in superior extremities</td>
</tr>
<tr>
<td>B2M (mg/L)</td>
<td>April 2006, 10.5</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>August 2006, 16.5</td>
</tr>
</tbody>
</table>
case, the autologous transplant was ruled out because of poor performance status of the patient.

Based on efficacy of bortezomib against B-cell malignancies and the experience in MCD described by Hess et al. [3], we decided to use bortezomib in a patient diagnosed with MCD-POEMS variant, refractory to previous treatment. The treatment was well tolerated, and the patient showed a definitive clinical improvement and sustained reduction of IL-6 cytokines requiring no further treatment after 4 years. The therapeutic efficacy demonstrated in this case by bortezomib supports the initiation of clinical studies evaluating the potential impact of this drug in the treatment of MCD.

References